Hannah Timmins

Current Appointments

Clinical Research Manager and Research Scientist

Key Research Areas

Motor Neurone Disease and Frontotemporal Dementia

Motor neurone disease

Frontotemporal dementia

Dementia

email hidden; JavaScript is required

02 9399 1071

Dr Hannah Timmins is a Clinical Research Manager and Research Scientist with a specialised focus on neurodegenerative diseases and neurophysiological assessments. She holds a PhD in Medicine from the University of Sydney, with her work spanning critical areas including Neuropathy, Motor Neurone Disease (MND), and Frontotemporal Dementia (FTD).

In her current role, Dr Timmins oversees large-scale, cross-institutional research programs, including the coordination of international clinical trials and collaborative research efforts, where she ensures rigorous scientific execution and operational efficiency. She plays a pivotal role in strategic research planning and the overall management of clinical research operations.

As a contributor to the advancement of neurodegenerative disease research, Dr Timmins’ current work centres on improving clinical outcomes for individuals affected by MND and other neurodegenerative diseases. She is dedicated to exploring novel diagnostic tools, biomarkers and treatment strategies that aim to slow disease progression and enhance quality of life.

Support this research

Publications

2024 Sep

Regional health priorities for dementia: a roadmap for the Western Pacific

View full journal-article on https://doi.org/10.1016/j.lanwpc.2024.101179

2024, 01 Aug

Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.

View full journal-article on https://europepmc.org/articles/PMC11316238

2024, 22 Jul

Diagnostic criteria for amyotrophic lateral sclerosis.

View full journal-article on https://doi.org/10.1097/WCO.0000000000001302

2024 Jul

Novel approaches to assessing upper motor neuron dysfunction in motor neuron disease/amyotrophic lateral sclerosis: IFCN handbook chapter

View full journal-article on https://doi.org/10.1016/j.clinph.2024.04.010

2024 Apr

Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy

View full journal-article on https://doi.org/10.1200/PO.23.00690

2024, 15 Feb

Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity.

View full journal-article on https://doi.org/10.6004/jnccn.2023.7083

2023, 24 May

Cortical hyperexcitability in amyotrophic lateral sclerosis: from pathogenesis to diagnosis.

View full journal-article on https://doi.org/10.1097/WCO.0000000000001162

2023, 05 May

Short tandem repeat expansions in sporadic amyotrophic lateral sclerosis and frontotemporal dementia.

View full journal-article on https://europepmc.org/articles/PMC10162670

2023, 01 Feb

Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.

View full journal-article on https://doi.org/10.6004/jnccn.2022.7074

2023 Feb

Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review

View full journal-article on https://doi.org/10.1007/s11764-021-00988-x

View all publications

Donate to us

Every dollar of community support enables our scientists to continue making life-changing discoveries that contribute to a brighter and healthier future.

Learn More